GW Pharmaceuticals PLC- (GWPH) Receives Average Recommendation of “Hold” from Brokerages

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) have earned a consensus rating of “Hold” from the eleven research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $150.29.

Several equities analysts have recently weighed in on the company. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Leerink Swann reissued a “buy” rating and set a $153.00 price target on shares of GW Pharmaceuticals PLC- in a report on Tuesday, January 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $192.00 price target (down from $208.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, February 5th. Finally, Bank of America lowered their price target on GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a “buy” rating on the stock in a report on Tuesday, February 6th.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at $127.32 on Wednesday. The firm has a market capitalization of $3,230.00, a price-to-earnings ratio of -14.40 and a beta of 2.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.34 and a current ratio of 11.44. GW Pharmaceuticals PLC- has a twelve month low of $92.65 and a twelve month high of $143.37.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.03) by ($0.40). The firm had revenue of $7.73 million for the quarter, compared to the consensus estimate of $2.18 million. GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. sell-side analysts predict that GW Pharmaceuticals PLC- will post -9.18 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Janus Henderson Group PLC increased its stake in shares of GW Pharmaceuticals PLC- by 2.6% in the 3rd quarter. Janus Henderson Group PLC now owns 717,729 shares of the biopharmaceutical company’s stock worth $72,842,000 after purchasing an additional 18,194 shares in the last quarter. Jennison Associates LLC increased its stake in shares of GW Pharmaceuticals PLC- by 0.4% in the 3rd quarter. Jennison Associates LLC now owns 492,480 shares of the biopharmaceutical company’s stock worth $49,982,000 after purchasing an additional 1,759 shares in the last quarter. Pictet Asset Management Ltd. increased its stake in shares of GW Pharmaceuticals PLC- by 102.6% in the 3rd quarter. Pictet Asset Management Ltd. now owns 355,263 shares of the biopharmaceutical company’s stock worth $36,056,000 after purchasing an additional 179,911 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of GW Pharmaceuticals PLC- by 18.0% in the 4th quarter. Alliancebernstein L.P. now owns 332,273 shares of the biopharmaceutical company’s stock worth $43,863,000 after purchasing an additional 50,780 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of GW Pharmaceuticals PLC- by 6.5% in the 4th quarter. Victory Capital Management Inc. now owns 261,390 shares of the biopharmaceutical company’s stock worth $34,506,000 after purchasing an additional 15,995 shares in the last quarter. Hedge funds and other institutional investors own 74.75% of the company’s stock.

WARNING: “GW Pharmaceuticals PLC- (GWPH) Receives Average Recommendation of “Hold” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/gw-pharmaceuticals-plc-gwph-receives-average-recommendation-of-hold-from-brokerages.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply